Oral health–related quality of life in breast cancer survivors

Jardim, Luísa Comerlato; Flores, Priscila Trindade; Araújo, Maria do Carmo; Chiesa, Juarez; Moraes, Cristina Machado Bragança de; Antoniazzi, Raquel Pippi

doi:10.1007/s00520-019-04792-3

Cited by 16 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jardim LC et al 10 In the last 12 months 85 women (56.3%) reported xerostomia. In the multivariate analysis, women with xerostomia and more than three restored teeth had, respectively, 2.92 times (95% Confidence Interval (CI) 1.20 to 7.09) and 1.98 times (95% CI 1.01 to 3.87) greater chance of having a negative impact on oral health-related quality of life when compared to women without xerostomia and those with fewer restorations.…”

Section: Authors Resultsmentioning

confidence: 97%

Xerostomia and breast cancer / Xerostomia e câncer de mama

Pinto

Westphal

Elias

2021

RPCF

View full text Add to dashboard Cite

Objetivo: identificar os estudos que descrevem a prevalência de xerostomia em pacientes com câncer de mama e em quimioterapia. Método: revisão integrativa, partindo da questão norteadora << Quais as evidências científicas sobre a prevalência de xerostomia em pacientes com câncer de mama e em quimioterapia? >>. Foi realizada uma busca nas bases de dados PubMed, LILACS e SciELO por meio dos Descritores em Ciências da Saúde. Foram encontrados 63 artigos, que foram analisados por dois pesquisadores seguindo os critérios de inclusão e exclusão. Resultados: a prevalência de xerostomia foi descrita em 10 artigos que utilizaram como método de avaliação escalas, questionários com respostas dicotômicas e sialometria. Conclusão: identificou-se uma prevalência de 47% a 77,3% de xerostomia durante a quimioterapia.

show abstract

Section: Authors Resultsmentioning

confidence: 97%

Xerostomia and breast cancer / Xerostomia e câncer de mama

Pinto

Westphal

Elias

2021

RPCF

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…In this context, previous studies showed that BC survivors treated with AIs have worse subjective oral health, periodontal health, and oral health-related quality of life [ 14 , 15 ]. Hence, bisphosphonate-related osteonecrosis of the jaws [ 16 ], oral lesions [ 15 ], caries [ 17 ], and periodontal tissue diseases (e.g., gingivitis and periodontitis) [ 18 , 19 ] may occur in a higher percentage of BC women undergoing cancer treatments and anti-osteoporotic drugs. Similarly, vitamin D plays a key role in different fields of medicine, including dentistry, and acts through several mechanisms, including cellular proliferation and differentiation, cell maturation, and innate immune system response [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Oral Health in Breast Cancer Women with Vitamin D Deficiency: A Machine Learning Study

Ferrillo

Migliario

Marotta

et al. 2022

JCM

View full text Add to dashboard Cite

Breast cancer (BC) survivors treated with aromatase inhibitors (AIs) commonly show several pathological issues, including poor oral health, bone health impairment, and vitamin D deficiency. However, to date, oral health issues in BC survivors treated with AIs have been poorly investigated and their relationship with vitamin D deficiency are far from being understood. This study aimed to evaluate the correlation between oral health and vitamin D status in BC survivors undergoing treatment with AIs through a machine learning approach. In this cross-sectional study, we included post-menopausal BC women with vitamin D deficiency undergoing AIs therapy. The outcome measures were the following: oral health indexes as the Decayed, Missing, and Filled Permanent Teeth Index (DMFT); serum levels of 25(OH)D3; Bone Mineral Density (BMD); and the diagnosis of osteoporosis. We included 41 post-menopausal BC women, mean aged 66.10 ± 8.47 years, with mean serum levels of vitamin D of 14.63 ± 6.62 ng/mL. Furthermore, 56.10% of patients had a diagnosis of osteoporosis and 36.59% were osteopenic. DMFT was significantly related to smoking (p-value = 0.005) and dental floss use (p-value = 0.001). There was a significant correlation between DMFT and vitamin D levels (Pearson’s r: −0.73; p-value = 0.001). The regression machine learning model showed that vitamin D status and the use of dental floss were the most relevant variables in terms of correlation with DMFT. In conclusion, vitamin D deficiency, inadequate use of dental floss, and smoking had a negative impact on oral health in BC women. Thus, vitamin D deficiency screening and supplementation and a prompt oral rehabilitation plan should be suggested and implemented in the complex treatment framework of BC survivors undergoing treatment with AIs.

show abstract

“…However, therapies for BC are associated with acute or late-onset oral complications, such as mucositis, pain, xerostomia, dental caries, osteoradionecrosis, changes in periodontal tissues, oral lesions, neurosensory changes and changes in the sense of taste [9,10]. Such dental problems have a negative impact on oral health-related quality of life in this population [11]. A recent study showed that AIs negatively affected tooth loss and attachment loss, while tamoxifen did not affect dental condition in women with breast cancer [12].…”

Section: Introductionmentioning

confidence: 99%

Association between tamoxifen and tooth loss in women with breast cancer

Sensever

Jardim

Ferrazzo

et al. 2022

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Investigate the effect of tamoxifen on the occurrence of tooth loss (TL) in breast cancer (BC) survivors. MethodsA cross-sectional study was conducted with 140 BC survivors using tamoxifen therapy.Sociodemographic, medical and dental data were evaluated. TL was determined using the M component of the Decayed, Missing and Filled Teeth (DMFT) index. Logistic regression models were run to determine associations between the independent variables and outcome (TL). ResultsMean TL was 12.96 (SD 8.88). Only three participants had lost no teeth and 10.7% were completely edentulous. Participants who used tamoxifen for more than 1 year had a higher mean missing teeth (13.99 vs. 10.45; P = 0.030). After the adjustments, the occurrence of more than 12 missing teeth was 2.75-fold higher among women who used tamoxifen for more than 1 year (95% CI: 1.06-7.12). Moreover, age over 65 years, referral for treatment by the public healthcare system, less use of dental services, xerostomia and a lower occurrence of dental caries remained associated with the loss of more than 12 teeth. ConclusionLonger use of tamoxifen was associated with greater tooth loss in breast cancer survivors. Clinical relevance:Based on estimates of the increase in cases of breast cancer, the prolonged use of tamoxifen for the treatment of this disease can exert an impact on oral health through the occurrence of tooth loss. These ndings can contribute to the planning and implementation of oral health care and prevention strategies for such patients.

show abstract

Oral health–related quality of life in breast cancer survivors

Cited by 16 publications

References 31 publications

Xerostomia and breast cancer / Xerostomia e câncer de mama

Xerostomia and breast cancer / Xerostomia e câncer de mama

Oral Health in Breast Cancer Women with Vitamin D Deficiency: A Machine Learning Study

Association between tamoxifen and tooth loss in women with breast cancer

Contact Info

Product

Resources

About